Glenmark Pharma's Q2 profits plunge 57% amid revenue decline

Glenmark Pharmaceuticals' financial performance in the second quarter of FY27 marked a significant downturn, with the company's net profit declining to ₹263.83 crore from higher levels in the corresponding prior-year period. The 56.8% profit decline was accompanied by a steeper revenue contraction, with total revenue falling to ₹4,247.32 crore, representing a 29.8% year-on-year decrease.

The substantial erosion in profitability was driven largely by exceptional items that weighed on the company's earnings during the quarter. These one-off charges impacted the pharmaceutical manufacturer's ability to convert its revenue base into bottom-line profits, offsetting operational performance across its portfolio.

The results underscore mounting pressures within India's pharmaceutical sector, where companies face headwinds including pricing pressures in key markets, currency fluctuations, and competitive intensity. Glenmark's performance reflects broader industry challenges that have affected multiple manufacturers during the fiscal year.

The company continues to navigate a complex market environment as it works toward stabilizing its operations and returning to growth trajectories. The full-year outlook and management's strategic responses to the current headwinds will be closely monitored by investors and industry analysts in coming quarters.